It may also have some metabolic effects
While GLP-1 based therapies are highly effective at managing weight reduction, gastrointestinal (GI) side effects, including nausea (2544 %), diarrhea (1932 %), vomiting (825 %), constipation (1223 %) and abdominal pain (510 %), were common in pivotal Phase 3 studies, although generally transient in nature [[40], [41], [42],46]
W., Heller S., Hels O
Choi says it may be easier to become frustrated or experience side effects that lead to discontinuing the medicine before understanding if it will truly work for you
Results Characteristics of participants We recruited 24 individuals with obesity into this study (Table 1)
While the 46% proteinuria reduction data positions atacicept with the potential to redefine care, the nephrology field eagerly awaits the final 2027 readout to confirm its definitive role in preserving long-term kidney function